{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:30:52Z","timestamp":1753893052323,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Traditional observational studies have yielded inconsistent findings regarding the association between COVID-19 and HBV\/HIV infections, as well as the protective effects of antiviral therapy against severe COVID-19. This study aimed to investigate the potential links between the current use of antiviral therapy and the rates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and symptoms of infection in patients with SARS-CoV-2 and HBV\/HIV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using a questionnaire-based survey, we recorded whether participants had been infected with SARS-CoV-2, and the symptoms and severity of COVID-19 after the illness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 756 participants, chi-square tests showed a higher incidence of COVID-19 in the HBV infection group (75.6%, <jats:italic>p<\/jats:italic> =\u202f0.047) and the HIV infection group (77.6%, <jats:italic>p<\/jats:italic> =\u202f0.036). These two groups exhibited fewer symptoms than the control group (<jats:italic>p<\/jats:italic> &amp;lt;\u202f0.001). The differences in the prevalence of most symptoms were also significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings suggest that patients with HBV or HIV infection have a higher risk of contracting SARS-CoV-2 than the general population; however, antiviral treatment relieves the symptoms of COVID-19.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1536794","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:06:40Z","timestamp":1741849600000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A questionnaire-based survey on the epidemiological and clinical characteristics of SARS-CoV-2 infection in patients with chronic HBV infection and HIV infection"],"prefix":"10.3389","volume":"13","author":[{"given":"Lu","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Jie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Fei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Qin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1136\/postgradmedj-2020-138234","article-title":"Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19)","volume":"96","author":"Umakanthan","year":"2020","journal-title":"Postgrad Med J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e14829","DOI":"10.1111\/ijcp.14829","article-title":"COVID-Q: validation of the first COVID-19 questionnaire based on patient-rated symptom gravity","volume":"75","author":"Spinato","year":"2021","journal-title":"Int J Clin Pract"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.12998\/wjcc.v8.i12.2554","article-title":"Epidemiological and clinical characteristics of COVID-19 patients in Hengyang, Hunan Province, China","volume":"8","author":"Zhong","year":"2020","journal-title":"World J Clin Cases"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1125246","DOI":"10.3389\/fimmu.2023.1125246","article-title":"The development of COVID-19 treatment","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3389\/fpubh.2020.00365","article-title":"Progress in the Research and Development of anti-COVID-19 drugs","volume":"8","author":"Huang","year":"2020","journal-title":"Front Public Health"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"104490","DOI":"10.1016\/j.bioorg.2020.104490","article-title":"Computational drug discovery and repurposing for the treatment of COVID-19: a systematic review","volume":"106","author":"Mohamed","year":"2021","journal-title":"Bioorg Chem"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1111\/jvh.13362","article-title":"Clinical characteristics in patients with SARS-CoV-2\/HBV co-infection","volume":"27","author":"Chen","year":"2020","journal-title":"J Viral Hepat"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3138\/canlivj-2020-0029","article-title":"HBV coinfection and in-hospital outcomes for COVID-19: a systematic review and meta-analysis","volume":"4","author":"Zhu","year":"2021","journal-title":"Can Liver J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/hep.31890","article-title":"Current and past infections of HBV do not increase mortality in patients with COVID-19","volume":"74","author":"Yip","year":"2021","journal-title":"Hepatol Baltim Md"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"6599","DOI":"10.3748\/wjg.v28.i46.6599","article-title":"Correlation between COVID-19 and hepatitis B: a systematic review","volume":"28","author":"He","year":"2022","journal-title":"World J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40121-022-00638-4","article-title":"Patients with COVID-19 and HBV coinfection are at risk of poor prognosis","volume":"11","author":"Yang","year":"2022","journal-title":"Infect Dis Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1017\/S0950268823000705","article-title":"The impact of HBV infection on clinical outcomes of COVID-19 patients: a systematic review and meta-analysis","volume":"151","author":"Guo","year":"2023","journal-title":"Epidemiol Infect"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00281-019-00744-5","article-title":"CD8+ T cell exhaustion","volume":"41","author":"Kurachi","year":"2019","journal-title":"Semin Immunopathol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e0258229","DOI":"10.1371\/journal.pone.0258229","article-title":"Association between chronic hepatitis B infection and COVID-19 outcomes: a Korean nationwide cohort study","volume":"16","author":"Kang","year":"2021","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19","volume":"19","author":"Chien","year":"2020","journal-title":"J Proteome Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1097\/QAD.0000000000002643","article-title":"Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study","volume":"34","author":"Inciarte","year":"2020","journal-title":"AIDS Lond Engl"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1016\/S2352-3018(20)30164-8","article-title":"Description of COVID-19 in HIV-infected individuals: a single-Centre, prospective cohort","volume":"7","author":"Vizcarra","year":"2020","journal-title":"Lancet HIV"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1590\/1806-9282.67.Suppl1.20200754","article-title":"Potential impact of the COVID-19 in HIV-infected individuals: a systematic review impact of the COVID-19 in HIV-infected individuals","volume":"1","author":"de Medeiros","year":"2021","journal-title":"Rev Assoc Medica Bras 1992"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12981-021-00427-y","article-title":"Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis","volume":"19","author":"Danwang","year":"2022","journal-title":"AIDS Res Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/jmv.25732","article-title":"Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China","volume":"92","author":"Zhu","year":"2020","journal-title":"J Med Virol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1002\/jmv.26077","article-title":"Clinical features and outcome of HIV\/SARS-CoV-2 coinfected patients in the Bronx, New York city","volume":"92","author":"Suwanwongse","year":"2020","journal-title":"J Med Virol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1089\/apc.2020.29005.com","article-title":"Why Aren\u2019t people living with HIV at higher risk for developing severe coronavirus disease 2019 (COVID-19)?","volume":"34","author":"Laurence","year":"2020","journal-title":"AIDS Patient Care STDs"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1536794\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:06:42Z","timestamp":1741849602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1536794\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":25,"alternative-id":["10.3389\/fpubh.2025.1536794"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1536794","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"article-number":"1536794"}}